Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Amgen (AMGN)

July 1, 2026 8:48 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $400.00 price target on Amgen (NASDAQ: AMGN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments